Primary Ciliary Dyskinesia Market to Grow at Highest Pace Owing to Rising Awareness About Early Diagnosis
Primary ciliary dyskinesia (PCD) is a rare genetic disorder that affects the cilia - microscopic hairs lining airway epithelial cells that help clear mucus and move particles in the airways and fallopian tubes. PCD causes respiratory and sinus infections that can damage the lungs. It is considered a rare disease with only 1 in 15,000-30,000 births affected by PCD.
The current treatment options focus on treating symptoms and complications to improve quality of life. It involves chest physiotherapy and treatment for lung infections using antibiotics, inhalers, or steroids. However, early diagnosis and treatment of Primary Ciliary Dyskinesia is crucial to slow the progression of lung disease.
The primary ciliary dyskinesia market is estimated to be valued at USD 538.2 Mn in 2024 and is expected to reach USD 784.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031. .
Key players operating in the primary ciliary dyskinesia market are AstraZeneca, Novartis, Vertex Pharmaceuticals, Bayer AG, Pfizer Inc.
Key Takeaways
Key players: Key players operating in the primary ciliary dyskinesia market are AstraZeneca, Novartis, Vertex Pharmaceuticals, Bayer AG, Pfizer Inc.
Growing demand: Increasing awareness about early diagnosis and treatment of PCD is driving the demand for diagnostic tests and supportive care drugs. Availability of newer diagnostic techniques is also fueling market growth.
Technological advancement: Developments in genetic testing techniques and advances in lung transplantation procedures are expected to offer new opportunities for PCD treatment in the coming years.
Market Trends
Increasing research on novel drug targets: Extensive research is ongoing to identify new drug targets and develop disease-modifying drugs to stop or slow PCD progression. Drugs targeting defects in ion transport and microtubule assembly show promise.
Rise in diagnostic screening programs: Initiatives to screen newborns and high-risk individuals through genetic testing and scanning electron microscopy are being undertaken to detect PCD early. This drives early treatment.
Market Opportunities
Drug development focus on symptom management: Significant opportunities exist in developing drugs for managing frequent infections, improving mucociliary clearance, and controlling inflammation in PCD patients.
Combination therapy approaches: Combining genetic therapy, cell-based therapy, and pharmacological interventions holds potential for management of multi-organ PCD manifestations.
Impact of COVID-19 on Primary Ciliary Dyskinesia Market growth:
The outbreak of COVID-19 pandemic has impacted the growth of primary ciliary dyskinesia market to some extent. Various lockdowns imposed worldwide led to decrease in screening tests and diagnostics for PCD during the initial few months of 2020. Majority of hospitals redirected their resources towards COVID-19 management due to surge in cases. This resulted in deferment of non-essential medical procedures and diagnostic tests including those for primary ciliary dyskinesia screening. However, telemedicine emerged as an effective alternative for initial consultation and diagnosis of suspected PCD cases. Many hospitals and clinics adopted telehealth solutions on a temporary basis to continue serving PCD patients albeit with certain limitations. With resumption of regular healthcare services as lockdowns were gradually lifted, PCD screening and diagnostics gained traction in subsequent months of 2020 and is anticipated to approach pre-pandemic levels by early 2022.
Europe has emerged as the most lucrative region in the primary ciliary dyskinesia market accounting for over 30% share in 2019. Countries like Germany, UK, France have witnessed increased awareness about PCD over the past decade contributing to higher testing rates. Established healthcare facilities with sophisticated diagnostic equipment in European nations facilitates accurate PCD diagnosis. Besides, universal healthcare coverage in many countries of Europe ensures PCD treatment affordability for patients. North America ranks second due to rising PCD prevalence estimates and newborn screening programs mandating PCD tests in several states of the US. Asia Pacific region is poised to offer lucrative growth opportunities during the forecast period with improving access to advanced diagnostics in China, India and other developing Asian countries.
Get more insights on: Primary Ciliary Dyskinesia Market
Author Bio:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)